Breakthrough study from UOS, BCI attracts global attention
Study
The study revealed that patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) who were taking statins at the start of modern targeted therapy (such as ibrutinib) were 61% less likely to die from cancer, 38% less likely to die from any cause, and 26% less likely to experience disease progression. Notably, statin use was not associated with an increased risk of severe side effects, supporting its safety profile in this context.
Dr. Karem Alzoubi, Dean of the College of Pharmacy at the University of Sharjah, commented: 'This outstanding research reflects our faculty's dedication to producing impactful scientific studies that address pressing healthcare challenges and contribute to innovative solutions for complex diseases like cancer.'
He added: 'The University of Sharjah places the highest importance on supporting scientific research, offering advanced infrastructure and state-of-the-art laboratories that enable our researchers to conduct world-class studies. The university also actively fosters collaboration with leading research institutions around the world, which helps promote knowledge exchange and elevate the quality of research outputs.'
Dr. Ahmad Abuhelwa, the study's lead author, explained, 'This is the first systematic evaluation of the link between statin use and survival outcomes in patients with CLL or SLL receiving modern targeted therapies. Our study analyzed data from 1,467 patients enrolled in four international clinical trials conducted between 2012 and 2019. The results highlight a strong association between statin use and improved survival, opening the door for future research that could ultimately benefit patients around the world.'
Dr Abuhelwa cautioned, however: 'While these results are highly encouraging, we cannot recommend statins as a cancer treatment based on this study alone, as it is observational and does not establish causality. We need future clinical trials to confirm whether statins can be used as a supportive treatment in this setting'.
Prof. Humaid Al Shamsi, CEO of the Burjeel Cancer Institute and co-author of the study, commented, 'As oncologists, we are always looking for safe and effective ways to improve patient survival. This study raises an exciting possibility—that a well-known and widely used medication like statins could enhance treatment outcomes without introducing additional risks.'
Findings
The findings of the study, which was published in the prestigious medical journal Blood Advances, have captured the attention of leading global media outlets, including The Telegraph, Daily Mail, The Independent, Associated Press, and Medscape. The findings have also been translated into several languages, including Spanish, Polish, Bulgarian, and Japanese, reflecting their broad international reach and impact.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Web Release
9 hours ago
- Web Release
Lilly's Jaypirca (pirtobrutinib), the first and only approved non-covalent (reversible) BTK inhibitor, met its primary endpoint in a head-to-head Phase 3 trial versus Imbruvica (ibrutinib) in CLL/SLL
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 BRUIN CLL-314 clinical trial of Jaypirca (pirtobrutinib), a non-covalent (reversible) Bruton's tyrosine kinase (BTK) inhibitor, versus Imbruvica (ibrutinib), a covalent BTK inhibitor, in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This study enrolled patients with treatment-naïve CLL/SLL and those who had been previously treated but were BTK inhibitor-naïve. The study met its primary endpoint of non-inferiority on overall response rate (ORR) as assessed by an independent review committee (IRC) in both the pre-treated and intent-to-treat populations. ORR favored pirtobrutinib with a nominal P-value for superiority1 (p <0.05). Progression free survival (PFS), a key secondary endpoint, was not yet mature at this analysis, but was trending in favor of pirtobrutinib. A formal PFS analysis testing for superiority is planned at a future analysis. No detriment was observed for overall survival (OS). BRUIN CLL-314 is the first ever head-to-head trial versus ibrutinib in CLL to include treatment-naïve patients. This important subpopulation (n=225) had the longest follow-up and a particularly pronounced PFS effect size in favor of pirtobrutinib. The overall safety profile of pirtobrutinib in BRUIN CLL-314 was similar to previously reported trials. Detailed results will be presented at a medical congress later in 2025. 'We launched the pirtobrutinib randomized development program with an ambitious suite of clinical trials, including head-to-head studies against modern standards of care and examinations of patient populations that reflect real world use, such as BTK inhibitor-pretreated patients,' said Jacob Van Naarden, executive vice president and president of Lilly Oncology. 'These data mark the second positive Phase 3 study in the program, as we continue to build evidence supporting the potential role of pirtobrutinib in treating people with CLL/SLL and hopefully enabling future regulatory approvals that allow physicians to use the medicine in various disease settings, whether treatment-naïve or BTK inhibitor-pretreated.' These data build on the previously reported positive results from the BRUIN Phase 1/2 trial and the Phase 3 BRUIN CLL-321 trial, the first randomized, controlled study ever conducted in an exclusively post-covalent BTK inhibitor population. The BRUIN CLL-313 Phase 3 study of pirtobrutinib versus chemoimmunotherapy in treatment naïve CLL/SLL is expected to read out later in 2025 and combined with the results of BRUIN CLL-314, will form the basis of regulatory submissions globally. For more information on the BRUIN Phase 3 clinical trial program, please visit
Gulf Today
5 days ago
- Gulf Today
Another alien theory surfaces, but doubts remain
According to a Harvard University scientist, the earth may be attacked by an alien object that has been hurtling through space towards our galaxy and which he spotted in July of this year. He thinks it might be an alien probe and may have weapons on board that the aliens plan to use to attack earth. Of course, all this is conjecture on his part because the operative word is 'may' and on top of that he has been known to propound outlandish theories about aliens and their existence. This time he thinks that it's possible that the probe might be hostile and it would come between the earth and the sun around November this year during which time they would prepare their weaponry! Alien theories have been around for decades. Did you know that there are so many videos circling on social media that claim that we may already be surrounded by aliens or even demons, many of whom, they claim, may have shape shifted into or taken over famous people? They've shown videos of some famous people with completely black eyes with no white parts to them, claiming that this is not the celebrity in question or, if it is, then that celebrity was always a demon. They've also shown camera footage of random people in crowds whose faces suddenly become distorted for no reason at all, claiming that was not human. I think they've been watching too many movies and shows about demons and aliens. Apparently, that one scene from the movie 'Signs' in which an alien creature walks by and peers directly into a camera is one of the most chilling scenes in a movie and may even be probable. I also think folk have watched far too many supernatural shows in which a demon's eyes are just one huge pupil that fills the eye socket and has no white part. Otherwise, how else would they know what a demon might look like? We need to bear in mind, and it is something about which astronomers keep reminding us, that the colourful photos we see from space are enhanced. Space is apparently not in colour and everything is actually black and white. So nothing is what it seems. Furthermore, to be honest with you, that object that is apparently heading towards us, is so far away that even with the most sophisticated telescopes, it would be impossible to tell a craft from a giant rock. The photo itself is a series of microscopic dots and dashes which have probably have also been enhanced. In an enthusiastic scientist's mind, connecting the dots can lead to outlandish conclusions. Alien theories have been around for decades. The most bizarre one is about the moon. Astronauts and scientists claim that the far side (that's the side we never see) has most likely already been colonised by aliens and that they were smart enough to do it on the side that we never see. Astronauts in movies claim seeing strange movements out of the corner of their eyes. If this object is indeed some kind of probe, do you think it would be hostile? Or doing some research about life on another planet? I would think it's a research and education mission instead of the 'War of the Worlds' scenario. Then I am reminded of Neil Degras Tyson's words about aliens and how they might see us. If they are far more advanced than we are, and they'd have to be to have the technology to travel that far at that speed, they'd see us as very inferior to them, almost the way we see worms on earth. If that is the case, they'd have no qualms about stepping all over us since we are, to them, brainless creatures. Could this Harvard scientist be wrong about this interstellar object? One thought does suddenly spring to mind. I've seen moon footage from space on social media (you just need to switch to your Facebook page for this) and many observers point out what looks like a tiny flying object crossing its atmosphere and one even shows a red blinking light nearby. How is it that this professor hasn't sounded the alarm on that one?
Zawya
5 days ago
- Zawya
Burjeel reports 129% increase in Q2 net profit, revenue grows 18.7%
UAE - Burjeel Holdings, a leading super-specialty healthcare services provider in MENA, has delivered a strong top-line growth of 18.7% to AED1,403 million ($381.98 million) in Q2 2025, driven by a 12.1% increase in patient footfall, higher patient yield, and the continued ramp-up of newly launched facilities across the network. Revenue in H1'25 rose 12.2% to AED2,677 million, with total patient visits reaching 3.4 million, the healthcare provider said. EBITDA rose 59.4% to AED306 million in Q2 2025, fueled by strong revenue growth, enhanced physician productivity, and better performance across recently ramped-up assets. This includes AED72 million in gains from lease liability derecognition following the Dubai Medeor Hospital acquisition. The EBITDA margin expanded 5.6 p.p. to 21.8%. In H1'25, EBITDA increased 14.2% to AED487 million, with a margin of 18.2%. Net profit surged 128.9% to AED148 million ($40.29 million) in Q2' 2025, reflecting margin expansion, enhanced operating leverage, and asset optimization. In H1'25, net profit rose 10.6% to AED187 million. Specialised Services, expansion Burjeel Holdings accelerated its strategic execution in Q2 2025 with a series of high-impact initiatives that deepened specialisation and broadened patient access. The group expanded its advanced oncology network, integrating Dubai's Advanced Care Oncology Center and opening new Burjeel Cancer Institute (BCI) clinics in Al Ain, Sharjah, and Oman, reinforcing its position as a regional leader in complex cancer care. The UAE's first dedicated cancer pharmacy was also inaugurated, strengthening oncology support infrastructure. In parallel, Burjeel launched a regional mental health platform through its joint venture Alkalma, opening four specialist mental health centers across the UAE and Saudi Arabia. This marked the first phase of a multi-year expansion strategy aimed at addressing rising demand for mental wellness services. In Saudi Arabia, the Group acquired a major physiotherapy facility in Riyadh under the PhysioTherabia platform, adding scale and unlocking turnaround potential through secured government contracts. Investments in operational resilience and access continued with the AED170 million acquisition of the Medeor Hospital Dubai building, converting long-term lease obligations into ownership and enhancing cost structure flexibility. The group also expanded its primary care footprint with a new medical center launched on Saadiyat Island, aligning with its growth strategy in high-yield urban catchments. In medical innovation, Burjeel launched Docktour, a transformative healthcare logistics joint venture with AD Ports Group, aiming to redefine how medical services and infrastructure are delivered to underserved and remote communities. Several specialised centers were introduced, including the region's first Al Muderis Osseointegration Clinic for advanced limb reconstruction, a state-of-the-art Epilepsy Monitoring Unit, and expanded capabilities in rare diseases, hematology, and metabolic research. Additionally, the Group continued its digital transformation with AI-powered diagnostics and led groundbreaking research in microgravity, aiming to transform care for patients with diabetes in space and on Earth. John Sunil, Chief Executive Officer of Burjeel Holdings, said: 'The second quarter delivered exceptionally strong results, with 19% revenue growth driven by a 12% increase in patient footfall and improved yield. EBITDA rose by 59%, accompanied by a margin uplift to 22%. This robust performance significantly strengthened the first-half outcome, underscoring Burjeel Holdings' resilience and long-term sustainable growth. 'These results reflect tangible progress in key operational areas such as physician manpower optimization, formulary management, and cost control, while our strategic focus on super-specialty care is beginning to yield measurable benefits, enhancing both revenue and profitability. We continue to invest in high-value services and next-generation care facilities to support long-term momentum. 'We also advanced key strategic priorities, reinforcing leadership in complex care across oncology, transplants, fertility, mental health, and diagnostics. Our oncology platform is now the UAE's largest private network, featuring new cancer clinics and cell and gene therapy capabilities. The Alkalma mental health platform is scaling regionally, alongside rehabilitation services through over 30 PhysioTherabia centers in Saudi Arabia. Additionally, we introduced the region's first Osseointegration Clinic for cutting-edge prosthetic care. 'In parallel with expanding our network of primary care and medical centers, we deepened partnerships with government and corporate stakeholders and accelerated digital integration through Oracle Health EMR and AI-powered tools. Building on this platform, we entered into pivotal partnerships in oncology, value-based care, diagnostics, and international healthcare innovation, establishing the Group as the healthcare partner of choice. 'Burjeel Holdings is uniquely positioned to capture significant opportunities across the region, supported by rising demand for complex care and a growing population. Our focus remains on converting recent investments into sustained expansion and margin improvement, while maintaining disciplined financial management to support long-term shareholder value. Net profit growth of 129% in the reporting quarter reinforces this trajectory and strengthens the foundation for consistent shareholder returns.' Growth drivers Oncology remained a core growth driver, with revenue rising 36.7% in Q2'25 and 38.1% in H1'25, underpinned by oncology network expansion and improved conversion in surgical and advanced therapies. Other specialties also recorded solid gains in H1'25, including urology (+18%), emergency medicine (+17%), cardiology (+16%), and gastroenterology (+13%). Inpatient footfall rose 17.7% in Q2'25, reflecting strong demand across key specialties and a ramp-up in elective surgeries post-Ramadan. The group performed 22,930 surgeries, up 18.7%, with momentum concentrated at Burjeel Medical City, Burjeel Specialty Hospital Sharjah, Lifecare Hospital Musaffah and Burjeel Royal Hospital Al Ain. Bed occupancy improved to 69%, up from 65% a year ago, and averaged 69% in H1'25. Inpatient volumes rose 14.6% over the first half. Outpatient footfall grew 12.0% in Q2'25, accelerating from 5.2% in Q1, driven by primary care and physiotherapy centers, along with robust demand in oncology, pediatrics, ophthalmology, and family medicine. Utilization improved to 68%, up from 65% in Q1'25, enabled by optimized hiring and scaling of clinical teams. Leading facilities included Burjeel Medical City, Lifecare Hospital Baniyas, and Burjeel Day Surgery Center Barari. In H1'25, outpatient volumes increased 8.6%.
